Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | LTA4H | P09960 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16399328 | 0.84 | — | — | |
| SCHEMBL5986834 | 0.82 | KDM4E (0.40) | PIK3CDKDM4ETNKS2MAPTPOLB | |
| SCHEMBL9278642 | 0.81 | KDM4E (0.34) | PIK3CDKDM4ETNKS2KMT2AGAA | |
| SCHEMBL18433366 | 0.81 | KDM4E (0.34) | PIK3CDKDM4ETNKS2 | |
| SCHEMBL16055768 | 0.80 | KMT2A (0.42) | LTA4HDPP4POLBKMT2AGAA | |
| SCHEMBL2375038 | 0.79 | LTA4H (0.33) | LTA4HDPP4 | |
| SCHEMBL8684586 | 0.78 | KMT2A (0.45) | DPP4POLBKMT2AALDH1A1 | |
| SCHEMBL6042973 | 0.78 | KMT2A (0.45) | DPP4POLBKMT2AALDH1A1 | |
| SCHEMBL28162736 | 0.78 | LTA4H (0.33) | LTA4HDPP4GAAALDH1A1 | |
| SCHEMBL12544225 | 0.78 | KDM4E (0.33) | PIK3CDKDM4EBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022212296-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. SHAW RESEARCH, LLC (US) | 2022-10-06 | — | — | WO | disclosed |
| CN-113557017-A | Inhibitors of cyclin-dependent kinase 7 and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2021-10-26 | — | — | CN | disclosed |
| US-10472352-B2 | Rac inhibitors | Geneyus LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190031647-A1 | RAC INHIBITORS | Geneyus LLC (US) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031647-A1 | RAC INHIBITORS | ARHGDIB, ARHGDIA, RAC1 | PIK3CD 186/4885KDM4E 2505/4885LTA4H 2089/4885 |
| US-10472352-B2 | Rac inhibitors | ARHGDIB, ARHGDIA, RAC1 | PIK3CD 186/4885KDM4E 2505/4885LTA4H 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.